{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4"},{"groupId":"OG001","value":"70.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Patients received an intradermal injection of C. albicans on the volar surface of the forearm on Day 1 and Week 24 for Group A or on Day 1 and Week 12 for Group B. Forty-eight to 72 hours after injection, patients were evaluated for a delayed-type hypersensitivity response by measuring the diameter of induration (palpable raised, hardened area of the forearm skin). A positive response to the C. albicans skin test was defined as at least 5 mm in diameter of induration.","groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG000","title":"Rituximab + Methotrexate (Group A)"},{"description":"Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG001","title":"Methotrexate (Group B)"}],"paramType":"NUMBER","populationDescription":"Skin test per-protocol population: Group A - All patients randomized to Group A who received any rituximab infusion, had Day 1 and Week 24 skin tests, and who provided complete diameter of induration readings. Group B - All patients randomized to Group B who had Day 1 and Week 12 skin tests and who provided complete diameter of induration readings.","reportingStatus":"POSTED","timeFrame":"Day 1 to Week 24 for Group A and Day 1 to Week 12 for Group B","title":"Percentage of Patients Who Maintained a Positive Response to the C. Albicans Skin Test From Day 1 to Week 24 for Group A or From Day 1 to Week 12 for Group B","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}